Prenatal Effects of Congenital Heart Disease (CHD) on Neurodevelopmental Outcome (D1879)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2012 by Columbia University
Sponsor:
Information provided by (Responsible Party):
Ismee Williams, Columbia University
ClinicalTrials.gov Identifier:
NCT00713635
First received: July 9, 2008
Last updated: November 19, 2012
Last verified: November 2012
  Purpose

The purpose of this study is to investigate the prenatal impact of abnormal cardiac structure on neurodevelopmental outcomes in children with congenital heart disease.


Condition
Congenital Heart Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Prenatal Effects of Congenital Heart Disease on Neurodevelopmental Outcome

Resource links provided by NLM:


Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Neurodevelopmental scores as measured by the Bayley Scales of Infant Development [ Time Frame: 18 months of age ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Neurologic Function as defined by neonatal electroencephalographic power and coherence as measured by a neonatal high-density EEG [ Time Frame: Neonatal EEG within 72 hours of birth ] [ Designated as safety issue: No ]
  • Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test) [ Time Frame: Fetal assessment between 18-24 wk GA ] [ Designated as safety issue: No ]
  • Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test) [ Time Frame: Fetal assessment between 28-32 wk GA ] [ Designated as safety issue: No ]
  • Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test) [ Time Frame: Fetal assessment between 34-38 wk GA ] [ Designated as safety issue: No ]
  • Neurologic Function as defined by neonatal electroencephalographic power and coherence as measured by a neonatal high-density EEG [ Time Frame: Neonatal EEG at 1 month of age ] [ Designated as safety issue: No ]

Estimated Enrollment: 24
Study Start Date: December 2010
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
2
Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
3
Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
4
Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group

Detailed Description:

Congenital heart disease (CHD) is the most common class of birth defect and is a major cause of infant and child death and morbidity, including neurodevelopmental delay. Children with severe forms of CHD are at high risk for a spectrum of neurocognitive difficulties that include learning disability, attention deficit and hyperactivity disorder, behavioral problems and mental retardation. The etiology of neurodevelopmental delay in children with CHD is not fully understood but is thought to be secondary to a combination of pre- and post-natal insults to the brain. It has been observed that fetuses with severe forms of CHD have abnormal blood flow to the brain as measured by Doppler ultrasound. This "centralization" or redirection of blood flow toward vital organs such as the brain has been shown to lead to abnormal brain development in other fetal diseases, such as intrauterine growth restriction. Evidence of the importance of prenatal brain development in the setting of CHD is amounting. Neonates with complex CHD demonstrate abnormalities of brain structure and blood flow prior to cardiothoracic surgery. , However, to date, associations between abnormal fetal brain blood flow and neonatal neurologic outcomes and brain function have not been established in the CHD population. Finally, newborns with CHD have been shown to have abnormalities in heart rate over a 24 hour period. This finding suggests that the autonomic nervous system, which controls heart rate and blood pressure, may not function properly in infants with CHD.

We propose that these changes in blood flows in the fetus with heart disease could be responsible in part for poor brain growth, abnormal brain structure and function and developmental delay in childhood. We will use routine obstetrical ultrasound and fetal echocardiograms to evaluate blood flow to vital organs and brain growth in fetuses with CHD. We will use non-invasive fetal monitors to measure fetal heart rate and movement. We will look at brain structure using Magnetic Resonance Imaging (MRI) in the fetus and newborn. Afterbirth, we will use non-invasive monitors to measure neonatal heart rate and blood pressure changes in response to a tilt, similar to what is experienced when placing an infant in a car seat. We will use a non-invasive monitor consisting of a sticker applied to the skin to measure the level of oxygen in the brain. We will also measure brain function in the newborn with an electroencephalogram(EEG) that records the electrical signaling between different parts of the brain using a special plastic hat like a swim cap. Regular physical exams with a pediatrician to measure growth and development will take place. A special test designed to detect learning disabilities will also be done when the child is 14 months old. This test will consist of talking with the child, reading stories, and showing the child pictures and colors. There will be no extra blood tests needed and none of the tests pose any risk to the mother, fetus, infant, or child.

The possible benefits to the child and the family will be early identification of any brain abnormality in the newborn period as well as learning disabilities in the toddler which will then allow the child to receive therapies designed to treat these problems. Studies show that early identification and treatment of learning disabilities are important to enhance the potential of the child.

  Eligibility

Ages Eligible for Study:   up to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Study subjects will consist of mothers and infants referred to the MSCHONY for evaluation of complex congenital heart disease consisting of: 1) single ventricle variant, such as hypoplastic left heart (HLHS); 2) Tetralogy of Fallot; 3) Transposition of the Great Vessels, and 4)Lung anomalies. We anticipate that 24 mothers and 24 fetuses/infants will be enrolled during the period of study. This will give us a total of 24 women-fetus/infant dyads or 48 subjects total (if one counts the mother and the fetus/infant separately).

Criteria

Inclusion Criteria:

  1. All women who present to CUMC between 18-24 wks gestational age with the following fetal diagnoses will be invited to participate:
  2. Hypoplastic Left Heart Syndrome (HLHS)
  3. Transposition of the Great Arteries (TGA)
  4. Tetralogy of Fallot (TOF)
  5. Lung anomalies consisting of either congenital cystic adenomatoid malformations or bronchogenic cysts

Exclusion Criteria:

  1. Documented fetal chromosomal anomaly
  2. Structural brain malformations
  3. Evidence of placental insufficiency or Intrauterine growth retardation
  4. Documented hydrops fetalis or sustained cardiac arrhythmias
  5. Anticipated delivery at an outside hospital
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00713635

Contacts
Contact: Ismee A Williams, MD, MS 212-342-1560 iib6@columbia.edu
Contact: William P Fifer, PhD 212-543-5696 wpf1@columbia.edu

Locations
United States, New York
Columbia University College of Physicians & Surgeons, Morgan Stanley Children's Hospital of New York Recruiting
New York, New York, United States, 10032
Contact: Ismee Williams    212-342-1560    iib6@columbia.edu   
Contact: William P Fifer, PhD    (212)543-5696    wpf1@columbia.edu   
Principal Investigator: Ismee A Williams, MD, MS         
Sponsors and Collaborators
Columbia University
Investigators
Principal Investigator: Ismee A Williams, MD, MS Columbia University
  More Information

No publications provided

Responsible Party: Ismee Williams, Asst Professor of Clinical, Department of Pediatrics Cardiology, Columbia University
ClinicalTrials.gov Identifier: NCT00713635     History of Changes
Other Study ID Numbers: AAAD1879
Study First Received: July 9, 2008
Last Updated: November 19, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:
Congenital Heart Disease

Additional relevant MeSH terms:
Heart Diseases
Heart Defects, Congenital
Cardiovascular Diseases
Cardiovascular Abnormalities
Congenital Abnormalities

ClinicalTrials.gov processed this record on July 28, 2014